Asthma and lower airway diseaseFixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up
Section snippets
Study population
The study population consisted of the previously described11 cohort of patients with fixed airflow obstruction due to asthma (n = 19) or COPD (n = 27). For consistency, in the present follow-up study we maintained the same terminology: fixed airflow obstruction due to asthma or COPD. The presence of fixed airflow obstruction, both in patients with asthma and those with COPD, was defined as a postbronchodilator FEV1/forced vital capacity ratio of less than 70% in baseline stable conditions
Results
Of the 46 patients with fixed airflow obstruction constituting the population of the original cross-sectional study,11 80% completed the 5-year follow-up (21 with a history of COPD and 16 with a history of asthma). Nine patients did not complete the study for the following reasons: 4 died (3 patients with a history of COPD and 1 with a history of asthma, P > .5), and 5 patients (3 patients with a history of COPD and 2 with a history of asthma, P > .5) refused consent.
Demographic and baseline
Discussion
This is a 5-year follow-up study conducted in a cohort of patients previously described cross-sectionally as having fixed airflow obstruction with either a history of asthma or COPD. We found that patients with fixed airflow obstruction due to either COPD or asthma had a greater postbronchodilator FEV1 decline compared with that seen in asthmatic patients with reversible airflow obstruction. The rate of lung function decline was similar in patients with fixed airflow obstruction due to asthma
References (45)
- et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone
Respir Med
(2007) - et al.
The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma
J Allergy Clin Immunol
(2008) - et al.
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study
Lancet
(2006) - et al.
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Lancet
(2009) - et al.
Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40
J Clin Epidemiol
(2001) - et al.
From COPD to chronic systemic inflammatory syndrome?
Lancet
(2007) - et al.
Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking
Gend Med
(2006) Global strategy for asthma management and prevention. NHLBI/WHO workshop report. 2002
(2008)National Institute of Health; National Heart Lung, and Blood Institute. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop report
(2008)
Pathogenesis of asthma
Clin Exp Allergy
Chronic obstructive pulmonary disease
N Engl J Med
Cellular and structural bases of chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Risk factors associated with irreversible airflow limitation in asthma
Curr Opin Allergy Clin Immunol
Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994
Arch Intern Med
Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma
Eur Respir J
Factors associated with persistent airflow limitation in severe asthma
Am J Respir Crit Care Med
15-year follow-up study of ventilatory function in adults with asthma
N Engl J Med
Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease
Am J Respir Crit Care Med
The overlap syndrome of asthma and COPD: what are its features and how important is it?
Thorax
Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation
Eur Respir J Suppl
Cited by (122)
Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol
2024, Journal of Controlled ReleasePredictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study
2023, The Lancet Respiratory MedicineThe 5T approach in asthma: Triple Therapy Targeting Treatable Traits
2022, Respiratory MedicineSmall Airway Disease in Asthma: Why is it so Important?
2022, Archivos de BronconeumologiaOscillometry and Asthma Control in Patients With and Without Fixed Airflow Obstruction
2022, Journal of Allergy and Clinical Immunology: In PracticeBronchodilator Responsiveness: An Underappreciated Biomarker for Asthma Exacerbations
2022, Journal of Allergy and Clinical Immunology: In Practice
Supported by the Italian Ministry of Health and the Italian Ministry of Education (MURST).
Disclosure of potential conflict of interest: M. Contoli has received consulting fees from Chiesi Farmaceutici and has received lecture fees from Boehringer Ingelheim and AstraZeneca. S. Baraldo has received lecture fees from Boehringer Ingelheim. M. Romagnoli has received lecture fees from AstraZeneca. G. Caramori has received lecture fees from Sigma Tau, has received research support from Novartis, and has served as an expert witness for GlaxoSmithKline. M. Saetta has received lecture fees from AstraZeneca, Farmindustria, GlaxoSmithKline, Abbott Laboratories, and Boehringer Ingelheim and has received research support from GlaxoSmithKline and AstraZeneca. L. M. Fabbri has received fees for lecturing, consultancies, and advisory boards from Nycomed, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche, and Pfizer and has received research support from Chiesi Farmaceutici, Nycomed, Boehringer Ingelheim, Pfizer, Roche, and Novartis. A. Papi has received fees for lecturing, consultancies, and the advisory board from Chiesi Farmaceutici; fees for lecturing and consultancies from GlaxoSmithKline; fees for lecturing from AstraZeneca, Boehringer Ingelheim, and Merck Sharp & Dohme; and research support from AstraZeneca, Chiesi Farmaceutici, Boehringer Ingelheim, and Merck Sharp & Dohme. The rest of the authors have declared that they have no conflict of interest.